LY3002813 for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 Dec 2015: Trial registered, NCT02624778
  2. 22 Dec 2015: Trial started, NCT02624778

The trials

NCT02624778: A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

State
Completed
Phase
Phase 1
People
61 taking part
Started
22 Dec 2015
Primary completion
28 Aug 2019
Arms
Part A: 10 Milligram Per Kilogram (mg/kg) LY3002813 SD, Part A: 20 mg/kg LY3002813 SD, Part A: 40 mg/kg LY3002813 SD, Part B: 10 mg/kg LY3002813 Q2W, Part C:10 mg/kg LY3002813 Q4W, Part C:20 mg/kg LY3002813 Q4W
Results
Posted on the registry
  1. 8 Dec 2015: Trial registered
  2. 22 Dec 2015: Trial started
  3. 28 Aug 2019: Trial completed
  4. 8 Oct 2024: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.